Storico di ricavi, utili e flussi di cassa dai bilanci ufficiali.
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors.
Vedi grafici interattivi e bilanci completi → Modello di valutazione (DCF) →
| Conto economico | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Entrate totali | $2.4B | $2.3B | $2.2B | $1.8B | $1.6B | $1.4B | $988M | $968M | $854M | $452M | $191M | $37M | $25M | $31M | $47M | $290M | $185M | $152M | $118M | $113M | $99M |
| Utile lordo | $2.4B | $2.2B | $2.1B | $1.8B | $1.6B | $1.4B | $951M | $935M | $827M | $437M | $185M | $33M | $23M | $30M | $47M | $290M | $185M | $152M | $118M | $113M | $98M |
| Margine lordo% | 96.4% | 96.4% | 96.5% | 96.0% | 96.4% | 96.3% | 96.3% | 96.6% | 96.9% | 96.7% | 96.6% | 89.5% | 91.9% | 96.4% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 99.8% | 99.2% |
| Risultato Operativo (EBIT) | $971M | $872M | $605M | $171M | $201M | $287M | $110M | $369M | $439M | $166M | ($28M) | ($121M) | ($224M) | ($201M) | ($122M) | $90M | ($91M) | ($122M) | ($179M) | ($157M) | ($127M) |
| Margine operativo % | 39.8% | 37.6% | 27.9% | 9.3% | 12.5% | 20.0% | 11.1% | 38.2% | 51.4% | 36.7% | -14.7% | -326.7% | -893.9% | -640.5% | -258.0% | 30.9% | -49.4% | -80.3% | -152.1% | -138.4% | -128.5% |
| Reddito netto | $861M | $783M | $521M | $208M | $182M | $231M | $112M | $321M | $690M | $154M | ($70M) | ($170M) | ($269M) | ($245M) | ($148M) | $76M | ($92M) | ($135M) | ($163M) | ($86M) | ($101M) |
| Margine netto% | 35.3% | 33.7% | 24.0% | 11.3% | 11.3% | 16.1% | 11.3% | 33.2% | 80.8% | 34.1% | -36.7% | -456.6% | -1069.4% | -781.0% | -311.2% | 26.1% | -49.9% | -89.1% | -138.2% | -76.1% | -102.9% |
| EBITDA | — | $922M | $719M | $283M | $222M | $300M | $119M | $378M | $452M | $167M | ($22M) | ($120M) | ($213M) | ($196M) | ($115M) | $100M | ($73M) | ($116M) | ($156M) | ($157M) | ($110M) |
| Utile per azione (EPS) | $3.17 | $2.78 | $1.76 | $0.65 | $0.56 | $0.72 | $0.35 | $1.02 | $2.21 | $0.49 | $-0.28 | $-0.81 | $-1.38 | $-1.33 | $-0.92 | $0.58 | $-0.85 | $-1.26 | $-1.54 | $-0.87 | $-1.17 |
| Azioni in circolazione (M) | — | 282M | 296M | 321M | 325M | 322M | 318M | 315M | 313M | 312M | 251M | 209M | 194M | 184M | 160M | 130M | 109M | 107M | 105M | 99M | 87M |
Fonte: bilanci pubblici della società (SEC). Verificare su SEC EDGAR prima di fare affidamento su qualsiasi cifra.
Stati patrimoniali, flussi di cassa, dati trimestrali e indici completi nel visualizzatore interattivo di EXEL. /companies/us/EXEL
Le informazioni di questo sito sono solo a scopo educativo e informativo; non costituiscono consulenza finanziaria. Non vengono pubblicati prezzi obiettivo né raccomandazioni.
About TickerBase · Data methodology & sources · Privacy · Terms